IONS

SEC source: 0000874015-21-000033 · edgar.xml · derivative · entry 4

O'NEIL PATRICK R. · CIK 0001564926 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,253

Underlying: Common Stock · 16,504 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000033 · edgar.xml · derivative · entry 3

O'NEIL PATRICK R. · CIK 0001564926 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,868

Underlying: Common Stock · 25,868 shares

Expires not disclosed

F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000033 · edgar.xml · nonDerivative · entry 2

O'NEIL PATRICK R. · CIK 0001564926 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,826

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-21-000033 · edgar.xml · nonDerivative · entry 1

O'NEIL PATRICK R. · CIK 0001564926 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,682

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-21-000031 · edgar.xml · derivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,754

Underlying: Common Stock · 10,655 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F4 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000031 · edgar.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,378

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-21-000031 · edgar.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,119

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-21-000029 · edgar.xml · derivative · entry 4

Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,256

Underlying: Common Stock · 7,503 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000029 · edgar.xml · derivative · entry 3

Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,753

Underlying: Common Stock · 15,753 shares

Expires not disclosed

F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000029 · edgar.xml · nonDerivative · entry 2

Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,903

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-21-000029 · edgar.xml · nonDerivative · entry 1

Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,621

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-21-000027 · edgar.xml · derivative · entry 4

Swayze Eric · CIK 0001791058 · EVP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,944

Underlying: Common Stock · 8,944 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000027 · edgar.xml · derivative · entry 3

Swayze Eric · CIK 0001791058 · EVP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,976

Underlying: Common Stock · 23,976 shares

Expires not disclosed

F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000027 · edgar.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,835

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-21-000027 · edgar.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,051

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-21-000025 · edgar.xml · nonDerivative · entry 1

Geary Richard S · CIK 0001442730 · EVP, Chief Development Offc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,306

F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 03/07/2019.

F1 · shares: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 03/07/2019.

SEC source: 0000874015-21-000019 · edgar.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,107

F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 6/20/2019.

F2 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 6/20/2019.

SEC source: 0000874015-21-000023 · edgar.xml · derivative · entry 1

Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,444

Underlying: Common Stock · 35,444 shares

Expires 2028-01-03

F1 · derivative.exercise_date: Grant on 01/04/2021 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/04/2021. 25% of the shares subject to the option will vest and become exercisable on 01/04/2022. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-21-000019 · edgar.xml · derivative · entry 2

Swayze Eric · CIK 0001791058 · EVP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,945

Underlying: Common Stock · 53,945 shares

Expires 2028-01-03

F1 · derivative.exercise_date: Grant on 01/04/2021 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/04/2021. 25% of the shares subject to the option will vest and become exercisable on 01/04/2022. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-21-000017 · edgar.xml · derivative · entry 1

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2028-01-03

F1 · derivative.exercise_date: Grant on 01/04/2021 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/04/2021. 25% of the shares subject to the option will vest and become exercisable on 01/04/2022. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-21-000013 · edgar.xml · derivative · entry 1

O'NEIL PATRICK R. · CIK 0001564926 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,203

Underlying: Common Stock · 58,203 shares

Expires 2028-01-03

F1 · derivative.exercise_date: Grant on 01/04/2021 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/04/2021. 25% of the shares subject to the option will vest and become exercisable on 01/04/2022. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-21-000011 · edgar.xml · derivative · entry 1

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,872

Underlying: Common Stock · 149,872 shares

Expires 2028-01-03

F1 · derivative.exercise_date: Grant on 01/04/2021 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/04/2021. 25% of the shares subject to the option will vest and become exercisable on 01/04/2022. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-21-000009 · edgar.xml · derivative · entry 1

HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,041

Underlying: Common Stock · 61,041 shares

Expires 2028-01-03

F1 · derivative.exercise_date: Grant on 01/04/2021 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/04/2021. 25% of the shares subject to the option will vest and become exercisable on 01/04/2022. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-21-000007 · edgar.xml · derivative · entry 1

Geary Richard S · CIK 0001442730 · EVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,107

Underlying: Common Stock · 51,107 shares

Expires 2028-01-03

F1 · derivative.exercise_date: Grant on 01/04/2021 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/04/2021. 25% of the shares subject to the option will vest and become exercisable on 01/04/2022. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-21-000005 · edgar.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Dev and Cml Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,513

Underlying: Common Stock · 54,513 shares

Expires 2028-01-03

F1 · derivative.exercise_date: Grant on 01/04/2021 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/04/2021. 25% of the shares subject to the option will vest and become exercisable on 01/04/2022. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-21-000002 · edgar.xml · derivative · entry 1

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,850

Underlying: Common Stock · 46,850 shares

Expires 2028-01-03

F1 · derivative.exercise_date: Grant on 01/04/2021 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/04/2021. 25% of the shares subject to the option will vest and become exercisable on 01/04/2022. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-20-000174 · edgar.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,464

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 11, 2020.

SEC source: 0000874015-20-000172 · edgar.xml · nonDerivative · entry 2

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Indirect · by wife

Disclosed balance after: 174

F3 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on January 2, 2020.

SEC source: 0000874015-20-000172 · edgar.xml · nonDerivative · entry 1

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Indirect · by trust

Disclosed balance after: 600,391

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.50 to $50.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4.

SEC source: 0000874015-20-000170 · edgar.xml · nonDerivative · entry 2

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Indirect · by trust

Disclosed balance after: 639,391

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020.

SEC source: 0000874015-20-000170 · edgar.xml · nonDerivative · entry 1

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Indirect · by trust

Disclosed balance after: 645,391

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020.

SEC source: 0000874015-20-000168 · edgar.xml · derivative · entry 3

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2021-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-20-000168 · edgar.xml · nonDerivative · entry 2

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,879

F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on April 3, 2019.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.10, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.

SEC source: 0000874015-20-000168 · edgar.xml · nonDerivative · entry 1

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,719

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on April 3, 2019.

SEC source: 0000874015-20-000166 · edgar.xml · derivative · entry 3

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2021-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-20-000166 · edgar.xml · nonDerivative · entry 2

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,476

F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 14, 2020.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00-$51.10, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.

SEC source: 0000874015-20-000166 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,423

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 14, 2020.

SEC source: 0000874015-20-000164 · edgar.xml · derivative · entry 3

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,947

Underlying: Common Stock · 0 shares

Expires 2021-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-20-000164 · edgar.xml · nonDerivative · entry 2

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,476

F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 14, 2020.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00-$51.70, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.

SEC source: 0000874015-20-000164 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,529

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 14, 2020.

SEC source: 0000874015-20-000162 · edgar.xml · derivative · entry 3

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,840

Underlying: Common Stock · 0 shares

Expires 2021-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-20-000162 · edgar.xml · nonDerivative · entry 2

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,879

F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on April 3, 2019.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.70, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.

SEC source: 0000874015-20-000162 · edgar.xml · nonDerivative · entry 1

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,039

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on April 3, 2019.

SEC source: 0000874015-20-000160 · edgar.xml · derivative · entry 3

HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2021-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-20-000160 · edgar.xml · nonDerivative · entry 2

HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,495

F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on October 2, 2020.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.85 to $50.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.

SEC source: 0000874015-20-000160 · edgar.xml · nonDerivative · entry 1

HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,175

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on October 2, 2020.

SEC source: 0000874015-20-000158 · edgar.xml · derivative · entry 5

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2021-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-20-000158 · edgar.xml · nonDerivative · entry 2

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,021

F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2019.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.85 to $50.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.

SEC source: 0000874015-20-000158 · edgar.xml · nonDerivative · entry 1

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,011

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2019.

SEC source: 0000874015-20-000156 · edgar.xml · derivative · entry 3

Geary Richard S · CIK 0001442730 · EVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2021-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.